lisocabtagene maraleucel
FDA Grants Accelerated Approval to Breyanzi for Follicular Lymphoma
The FDA has granted accelerated approval to Breyanzi for adults with relapsed or refractory follicular lymphoma who ...
MAY 17, 2024
Breyanzi Approved for Adults With Relapsed/Refractory CLL or SLL
The FDA granted accelerated approval of Breyanzi for the treatment of adult patients with relapsed/refractory CLL ...
MARCH 20, 2024
New CAR T-Cell Therapy Breyanzi Approved for R/R B-Cell Lymphoma
The FDA approved the CD19-directed chimeric antigen receptor T-cell immunotherapy lisocabtagene maraleucel ...
FEBRUARY 15, 2021
Load more